New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 16, 2018 - The FDA announced the approval Cosmo Pharmaceuticals’ Aemcolo (rifamycin), for the treatment of travelers’ diarrhea (TD) caused by non-invasive strains of Escherichia coli (E. coli) in adults.
Download PDF
Return to publications
